PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Newly identified protein function protects cells during injury

2012-06-08
(Press-News.org) CINCINNATI – Scientists have discovered a new function for a protein that protects cells during injury and could eventually translate into treatment for conditions ranging from cardiovascular disease to Alzheimer's.

Researchers report online June 7 in the journal Cell that a type of protein called thrombospondin activates a protective pathway that prevents heart cell damage in mice undergoing simulated extreme hypertension, cardiac pressure overload and heart attack.

"Our results suggest that medically this protein could be targeted as a way to help people with many different disease states where various organs are under stress,'' said Jeffery Molkentin, PhD, lead investigator and a researcher at Cincinnati Children's Hospital Medical Center and the Howard Hughes Medical Institute. "Although more study is needed to determine how our findings might be applied clinically, a possible therapeutic strategy could include a drug or gene therapy that induces overexpression of the protein in tissues or organs undergoing injury."

Thrombospondin (Thbs) proteins are produced by the body in cells where tissues are being injured, reconfigured or remodeled, such as in chronic cardiac disease. They appear in part of the cell's internal machinery called the endoplasmic reticulum. There, Thbs triggers a stress response process to regulate production of other proteins and help correct or rid cells of proteins that misfold and lose their form and intended function. Misfolded proteins help drive tissue damage and organ dysfunction.

The researchers zeroed in on how one thrombospondin protein (Thbs4) activates cellular stress responses in mice bred to overexpress the protein in heart cells. They compared how the hearts of the Thbs4-positive mice responded to simulated stress and injury to mice not bred to overexpress cardiac-specific Thbs4.

Overexpression of Thbs4 had no effect on the animals prior to cardiac stress – although during simulated hypertension and cardiac infarction the protein reduced injury and protected them from death. Mice not bred for Thbs4 overexpression were extremely sensitive to cardiac injury, according to Molkentin, a member of the Division of Molecular Cardiovascular Biology and Cincinnati Children's Heart Institute.

The researchers reported that overexpressed Thbs4 enhanced the ability of heart cells to secrete helpful proteins, resolve misfolded proteins and properly reconstruct extracellular matrix – connective tissues that help give the heart functional form and structural integrity.

Critical to the stress response process was Thbs4 activating and regulating a transcription factor called Aft6alpha. Transcription factors help decode genetic instructions of other genes to control their expression. In the case of Aft6alpha in the heart, it helps mediate repair processes. When Aft6alpha is activated by Thbs4, the endoplasmic reticulum in cells expands and the production of chaperone molecules and other repair proteins is enhanced.

Mice bred not to overexpress cardiac Thbs4 did not exhibit activated Aft6alpha or robust repair processes following cardiac injury, leading to their poor outcomes.

Molkentin said the research team continues to examine the Thbs-dependent stress response pathway to better understand the involved processes. This includes seeing how the pathway affects laboratory models of neurodegenerative diseases like Parkinson's, Alzheimer's and amyotrophic lateral sclerosis

###Funding support for the study came from the National Institutes of Health and Howard Hughes Medical Institute.

Collaborating on the study – along with first author Jeffrey M. Lynch, a member of the Molkentin lab – were researchers from the Department of Pediatrics, Cincinnati Children's and the University of Cincinnati (UC), the Department of Surgery at UC and researchers from Kyoto University in Japan, Columbia University in New York and Beth Israel Deaconess Hospital and Harvard Medical School, Boston.

About Cincinnati Children's Cincinnati Children's Hospital Medical Center ranks third in the nation among all Honor Roll hospitals in U.S.News and World Report's 2012 Best Children's Hospitals ranking. It is ranked #1 for neonatology and in the top 10 for all pediatric specialties. Cincinnati Children's is one of the top two recipients of pediatric research grants from the National Institutes of Health. It is internationally recognized for improving child health and transforming delivery of care through fully integrated, globally recognized research, education and innovation. Additional information can be found at www.cincinnatichildrens.org.


ELSE PRESS RELEASES FROM THIS DATE:

Report addresses challenges in implementing new diagnostic tests where they are needed most

2012-06-08
Easy-to-use, inexpensive tests to diagnose infectious diseases are urgently needed in resource-limited countries. A new report based on an American Academy of Microbiology colloquium, "Bringing the Lab to the Patient: Developing Point-of-Care Diagnostics for Resource Limited Settings," describes the challenges inherent in bringing new medical devices and technologies to the areas of the world where they are needed most. Point-of-care diagnostics (POCTs) bypass the need for sophisticated laboratory systems by leveraging new technologies to diagnose infectious diseases and ...

11 integrated health systems form largest private-sector diabetes registry in US

2012-06-08
(PORTLAND, Ore.) —June 07, 2012—Eleven integrated health systems, with more than 16 million members, have combined de-identified data from their electronic health records to form the largest, most comprehensive private-sector diabetes registry in the nation. According to a new study published today in the Centers for Disease Control and Prevention's Preventing Chronic Disease, the SUPREME-DM DataLink provides a unique and powerful resource to conduct population-based diabetes research and clinical trials. "The DataLink will allow us to compare more prevention and ...

U Alberta finds weakness in armor of killer hospital bacteria

2012-06-08
There's new hope for development of an antibiotic that can put down a lethal bacteria or superbug linked to the deaths of hundreds of hospital patients around the world. Researchers from the University of Alberta-based Alberta Glycomics Centre found a chink in the molecular armour of the pathogen Acinetobacter baumannii. The bacteria first appeared in the 1970's and in the last decade it developed a resistance to most antibiotics. U of A microbiologist Mario Feldman identified a mechanism that allows Acinetobacter baumannii to cover its surface with molecules knows ...

Personalizing biologic treatment to individual patients with rheuatoid arthritis is cost-effective

2012-06-08
Berlin, Germany, June 7 2012: Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tailoring biologic treatment to individual patients with rheumatoid arthritis (RA) can reduce total costs by €2,595,557 per 272 patients over 3 years (95 percentile range -€2,983,760 to -€2,211,755), whilst increasing effectiveness by an average of 3.67 quality-adjusted life years (QALYs)*. Cost savings were mostly on drug costs. The Dutch study, which investigated 272 patients with RA starting adalimumab treatment, measured ...

Treatment with anti-TNFs reduces the risk of cardiovascular events in rheumatoid arthritis

2012-06-08
Berlin, Germany, June 7 2012: Results from a retrospective analysis of contemporary data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, predict, based on estimates from a multivariate regression model, that the cumulative use of anti-tumour necrosis factor drugs (anti-TNFs) for one, two, or three years is associated with reduced risk of cardiovascular events by 24%, 42% and 56% in patients with rheumatoid arthritis (RA) respectively, compared to not using anti-TNF therapies (adjusting for background use of methotrexate or other ...

Nearly two-thirds of American osteoporotic hip fractures are seen in the extreme elderly

2012-06-08
Berlin, Germany, June 7 2012: A new American study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, calls for more aggressive management of osteoporosis in the extreme elderly as the true impact of osteoporotic hip fractures in those aged 80 years or older is unveiled. Via the Nationwide Inpatient Sample (NIS), 4.3 million patients over the age of 65 with osteoporotic hip fractures were studied. Results showed that 67.3% of hip fractures occurred in the extreme elderly, increasing from 172,209 in 1993 to 180,428 in 2008. This ...

Patients taking certolizumab pegol are twice as likely to achievE ACR20 compared to placebo

2012-06-08
Berlin, Germany, June 7 2012: A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients treated with certolizumab pegol (CZP) were twice as likely to meet the primary endpoint of ACR20* response at week 12 than those on placebo: 58% on CZP200mg Q2W; and 51.9% on CZP 400 mg Q4W compared to 24.3% on placebo. This randomised, placebo controlled, 24 week period of an ongoing Phase III study of 409 patients indicated that more patients treated with both doses of CZP achieved ACR50* and ACR70* response ...

Control of disease activity and biologic treatment increase life expectency in RA patients

2012-06-08
Berlin, Germany, June 7 2012: According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with rheumatoid arthritis (RA) who are prescribed biologic treatments have a significantly lower mortality risk (adjusted hazard ratio [HR]: 0.61) than those just treated with traditional disease modifying anti-rheumatic drugs (DMARDs).The study also found the mortality was similar irrespective of the method of action of biologics (anti-tumour necrosis factor drugs [anti-TNFs] or rituximab). Results of the German study ...

Treatment with anti-TNFs can increase the risk of shingles by up to 75 percent

2012-06-08
Berlin, Germany, June 7 2012: Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional disease modifying anti-rheumatic drugs (DMARDs), according to a meta-analysis presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism. "Anti-TNFs, such as infliximab, adalimumab and etanercept have become the treatment of choice for patients with inflammatory rheumatic diseases who ...

Head-to-head study in RA shows that abatacept has comparable efficacy to adalimumab

2012-06-08
Berlin, Germany, June 7 2012: Data from one of the few head-to-head trials in rheumatoid arthritis (RA) presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that at one year, 64.8% of patients receiving abatacept (Orencia) and 63.4% of patients receiving adalimumab (Humira) achieved ACR20*. The Phase IIIb AMPLE study (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) was carried out in 646 biologic-naïve patients with active RA and inadequate response to methotrexate. ...

LAST 30 PRESS RELEASES:

Freeze-framing the cellular world to capture a fleeting moment of cellular activity

Computer hardware advance solves complex optimization problems

SOX2: a key player in prostate cancer progression and treatment resistance

Unlocking the potential of the non-coding genome for precision medicine

Chitinase-3-like protein 1: a novel biomarker for liver disease diagnosis and management

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: August 22, 2025

Charisma Virtual Social Coaching named a finalist for Global Innovation Award

From the atmosphere to the abyss: Iron's role in Earth's climate history

US oil and gas air pollution causes unequal health impacts

Scientists reveal how microbes collaborate to consume potent greenhouse gas

UMass Amherst kinesiologist receives $2 million ‘outstanding researcher’ award from NIH

Wildfire peer review report for land Brandenburg, Germany, is now online

Wired by nature: Precision molecules for tomorrow's electronics

New study finds hidden body fat is linked to faster heart ageing

How a gift card could help speed up Alzheimer’s clinical research

Depression and anxiety symptoms in adults displaced by natural disasters

Cardiovascular health at the intersection of race and gender in Medicare fee for service

World’s first observation of the transverse Thomson effect

Powerful nodes for quantum networks

Mapping fat: How microfluidics and mass spectrometry reveal lipid landscapes in tiny worms

ATOX1 promotes hepatocellular carcinoma carcinogenesis via activation of the c-Myb/PI3K/AKT signaling pathway

Colibactin-producing E. coli linked to higher colorectal cancer risk in FAP patients

Animal protein not linked to higher mortality risk, study finds

Satellite insights into eutrophication trends on the Qinghai–Tibet plateau

Researchers develop an innovative method for large-scale analysis of metabolites in biological samples

Asteroid Bennu is a time capsule of materials bearing witness to its origin and transformation over billions of years

New AI model can help extend life and increase safety of electric vehicle batteries

Wildfires can raise local death rate by 67%, shows study on 2023 Hawaiʻi fires

Yogurt and hot spring bathing show a promising combination for gut health

Study explains how lymphoma rewires human genome

[Press-News.org] Newly identified protein function protects cells during injury